Back to top
more

Molina Healthcare (MOH)

(Delayed Data from NYSE)

$190.71 USD

190.71
1,472,768

+8.15 (4.46%)

Updated Sep 24, 2025 04:00 PM ET

After-Market: $190.71 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 5% (234 out of 246)

Industry: Medical - HMOs

Zacks News

Zacks Equity Research

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Zacks Equity Research

Evaluating Molina Healthcare's (MOH) Future View: Hold or Fold?

Molina Healthcare's (MOH) top line is poised to gain from rising premium revenues and investment income.

Zacks Equity Research

Molina (MOH) Up 2.7% Since Last Earnings Report: Can It Continue?

Molina (MOH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

The Joint (JYNT) to Report Q4 Earnings: Here Are the Key Drivers

The Joint's (JYNT) fourth-quarter 2023 results are likely to reflect higher expenses and patient volumes.

Zacks Equity Research

Community Health (CYH) Q4 Earnings Miss, Revenues Up Y/Y

Community Health (CYH) expects net operating revenues in the range of $12.3-$12.7 billion for 2024.

Zacks Equity Research

Pediatrix's (MD) Q4 Earnings Miss Due to Soft Patient Volumes

Pediatrix's (MD) Q4 results were hit by an increase in overall cost level resulting from higher same-unit clinical compensation costs. Yet, an impressive 2024 adjusted EBITDA guidance is likely to provide relief to investors.

Zacks Equity Research

Zacks Industry Outlook Highlights Cigna, Centene and Molina Healthcare

Cigna, Centene and Molina Healthcare have been highlighted in this Industry Outlook article.

Debasmita Chatterjee headshot

3 HMO Stocks in Focus Despite High Tech Costs & Nursing Shortage

Growing customer base and M&A strategies are likely to aid the Medical-HMO industry. However, escalating expenses and a dearth in the availability of medical personnel are concerning. Stocks like CI, CNC and MOH are likely to navigate the industry storms.

Zacks Equity Research

Stock Market News for Feb 9, 2024

Wall Street closed higher on Thursday as strong earnings data boosted market participants¿¿¿ confidence on risky assets like equities.

Zacks Equity Research

Molina Healthcare (MOH) Q4 Earnings Beat on Premium Growth

Molina Healthcare (MOH) expects adjusted EPS to be at a minimum of $23.5 in 2024, which represents a year-over-year improvement of 12.5%.

Zacks Equity Research

Here's Why Molina (MOH) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Molina (MOH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Molina (MOH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Molina (MOH) Surpasses Q4 Earnings and Revenue Estimates

Molina (MOH) delivered earnings and revenue surprises of 1.62% and 8.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Will a Fall in Medicaid Customers Hurt Molina's (MOH) Q4 Earnings?

Molina Healthcare's (MOH) Q4 performance is likely to have been hurt by escalating medical care costs, and a decline in Medicaid and Marketplace membership, partly offset by growing Medicare premiums.

Zacks Equity Research

Gear Up for Molina (MOH) Q4 Earnings: Wall Street Estimates for Key Metrics

Besides Wall Street's top -and-bottom-line estimates for Molina (MOH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Zacks Equity Research

Cigna (CI) Surpasses Q4 Earnings and Revenue Estimates

Cigna (CI) delivered earnings and revenue surprises of 4.14% and 4.77%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Molina (MOH) Reports Next Week: Wall Street Expects Earnings Growth

Molina (MOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sumit Singh headshot

Pick These 4 Stocks With Amazing Interest Coverage Ratio

A company that is capable of generating earnings well above its interest expense can withstand financial hardship. MOH, ATO, AMZN and OPCH are sound enough to meet financial obligations.

Zacks Equity Research

Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?

Smart Beta ETF report for FXH

Zacks Equity Research

Molina Healthcare, Inc (MOH) Hits Fresh High: Is There Still Room to Run?

Molina (MOH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Molina Healthcare (MOH) Up 26.9% in 6 Months: What Lies Ahead?

Molina Healthcare (MOH) is likely to keep growing on the back of increases in investment income and Medicare premiums.

Zacks Equity Research

Should Value Investors Buy Centene (CNC) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

Strength Seen in Select Medical (SEM): Can Its 11.3% Jump Turn into More Strength?

Select Medical (SEM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.